ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma

Blood

Volumn 100, Issue 4, 2002, Pages 1430-1437

  Grønbaek, Kirsten ^a,b,c,d   Worm, Jesper ^a,b,c,d   Ralfkiaer, Elisabeth ^a,b,c,d   Ahrenkiel, Vibeke ^a,b,c,d   Hokland, Peter ^a,b,c,d   Guldberg, Per ^a,b,c,d  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; ATM PROTEIN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ATAXIA TELANGIECTASIA; ATM GENE; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; FEMALE; FOLLICULAR LYMPHOMA; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; GERM CELL; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RANDOMIZATION; RNA SPLICING; SOMATIC MUTATION; T CELL LEUKEMIA; T CELL LYMPHOMA; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 0037103190     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0382     Document Type: Article

References (53)

1. A single ataxia telangiectasia gene with a product similar to PI-3 kinase
2. Leukemia and lymphoma in ataxia telangiectasia
3. Mortality rates among carriers of ataxia-telangiectasia mutant alleles
4. Incidence of cancer in 161 families affected by ataxia-telangiectasia
5. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries
6. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia
7. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia
8. ATM is usually rearranged in T-cell prolymphocytic leukaemia
9. Inactivation of the ATM gene in T-cell prolymphocytic leukemias
10. Mantle cell lymphoma is characterized by inactivation of the ATM gene
11. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances
12. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia
13. ATM mutations in B-cell chronic lymphocytic leukemia
14. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
15. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage
16. DNA double-strand breaks: Signaling, repair and the cancer connection
17. The many substrates and functions of ATM
18. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation
19. ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation
20. Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: Correlation with clinicobiologic features
21. Deletions at 11q23 in different lymphoma subtypes
22. ATM gene deletion in patients with adult acute lymphoblastic leukemia
23. The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas
24. ATM associates with and phosphorylates p53: Mapping the region of interaction
25. Activation of the ATM kinase by ionizing radiation and phosphorylation ot p53
26. The INK4a/ARF network in tumour suppression
27. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion
28. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma
29. Single-step DGGE-based mutation scanning of the p53 gene: Application to genetic diagnosis of colorectal cancer
30. Genomic organization of the ATM gene
31. Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis
32. Mutational analysis of oncogenes and tumor suppressor genes in human cancer using denaturing gradient gel electrophoresis (DGGE)
33. Double-gradient DGGE for optimized detection of DNA point mutations
34. Characterization of ATM gene mutations in 66 ataxia telangiectasia families
35. A frequent polymorphism of the gene mutated in ataxia telangiectasia
36. Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays
37. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
38. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus
39. Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia
40. CpG-rich islands and the function of DNA methylation
41. Ataxia-telangiectasia and T-cell leukemias: No evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL
42. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene
43. Cancer risk in ATM heterozygotes: A model of phenotypic and mechanistic differences between missense and truncating mutations
44. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients
45. p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation
46. The DNA damage response: Putting checkpoints in perspective
47. ATM and ATR: Networking cellular responses to DNA damage
48. Atm-deficient mice: A paradigm of ataxia telangiectasia
49. Dual roles of ATM in the cellular response to radiation and in cell growth control
50. Genetic interactions between ATM and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints
51. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled ATM function
52. Ataxia-telangiectasia: Phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity